Hepatitis Monthly

Published by: Kowsar

The Clinical Significance of Serum Apoptotic Cytokeratin 18 Neoepitope M30 (CK-18 M30) and Matrix Metalloproteinase 2 (MMP-2) Levels in Chronic Hepatitis B Patients with Cirrhosis

Sua Sumer 1 , * , Nazlim Aktug Demir 2 , Servet Kölgelier 3 , Ahmet Cagkan Inkaya 4 , Abdullah Arpaci 5 , Lütfi Saltuk Demir 6 and Onur Ural 1
Authors Information
1 Department of Infectious Diseases and Clinical Microbiology, Selcuk University, Faculty of Medicine, Konya, Turkey
2 Department of Infectious Diseases and Clinical Microbiology, Adiyaman State Hospital, Adiyaman, Turkey
3 Department of Infectious Diseases and Clinical Microbiology, Adiyaman University, Faculty of Medicine, Adiyaman, Turkey
4 Department of Internal Medicine, Division of Infectious Diseases, Hacettepe University, Faculty of Medicine, Ankara, Turkey
5 Department of Biochemistry, Adiyaman University, Faculty of Medicine, Adiyaman, Turkey
6 Public Health Management Center, Konya, Turkey
Article information
  • Hepatitis Monthly: June 01, 2013, 13 (6); e10106
  • Published Online: June 26, 2013
  • Article Type: Research Article
  • Received: January 3, 2013
  • Revised: April 8, 2013
  • Accepted: May 25, 2013
  • DOI: 10.5812/hepatmon.10106

To Cite: Sumer S, Aktug Demir N, Kölgelier S, Cagkan Inkaya A, Arpaci A, et al. The Clinical Significance of Serum Apoptotic Cytokeratin 18 Neoepitope M30 (CK-18 M30) and Matrix Metalloproteinase 2 (MMP-2) Levels in Chronic Hepatitis B Patients with Cirrhosis, Hepat Mon. 2013 ; 13(6):e10106. doi: 10.5812/hepatmon.10106.

Copyright © 2013, Kowsar Corp. This is an open-access article distributed under the terms of the Creative Commons Attribution-NonCommercial 4.0 International License (http://creativecommons.org/licenses/by-nc/4.0/) which permits copy and redistribute the material just in noncommercial usages, provided the original work is properly cited.
1. Background
2. Objectives
3. Patients and Methods
4. Results
5. Discussion
  • 1. Hadziyannis SJ, Papatheodoridis GV. Hepatitis B e antigen-negative chronic hepatitis B: natural history and treatment. Semin Liver Dis. 2006; 26(2): 130-41[DOI][PubMed]
  • 2. Lok Anna SF, McMahon Brian J. Chronic hepatitis B. Hepatology. 2007; 45(2): 507-39
  • 3. McMahon BJ. The natural history of chronic hepatitis B virus infection. Semin Liver Dis. 2004; 24 Suppl 1: 17-21[DOI][PubMed]
  • 4. Cheong JY, Kim DJ, Hwang SG, Yang JM, Kim YB, Park YN, et al. Serum markers for necroinflammatory activity in patients with chronic viral hepatitis and normal or mildly elevated aminotransferase levels. Liver Int. 2011; 31(9): 1352-8[DOI][PubMed]
  • 5. Afdhal NH, Nunes D. Evaluation of liver fibrosis: a concise review. Am J Gastroenterol. 2004; 99(6): 1160-74[DOI][PubMed]
  • 6. Bedossa P, Dargere D, Paradis V. Sampling variability of liver fibrosis in chronic hepatitis C. Hepatology. 2003; 38(6): 1449-57[DOI][PubMed]
  • 7. Bravo AA, Sheth SG, Chopra S. Liver biopsy. N Engl J Med. 2001; 344(7): 495-500[DOI][PubMed]
  • 8. Myers RP, Tainturier MH, Ratziu V, Piton A, Thibault V, Imbert-Bismut F, et al. Prediction of liver histological lesions with biochemical markers in patients with chronic hepatitis B. J Hepatol. 2003; 39(2): 222-30[PubMed]
  • 9. Regev A, Berho M, Jeffers LJ, Milikowski C, Molina EG, Pyrsopoulos NT, et al. Sampling error and intraobserver variation in liver biopsy in patients with chronic HCV infection. Am J Gastroenterol. 2002; 97(10): 2614-8[DOI][PubMed]
  • 10. Ljumovic D, Diamantis I, Alegakis AK, Kouroumalis EA. Differential expression of matrix metalloproteinases in viral and non-viral chronic liver diseases. Clin Chim Acta. 2004; 349(1-2): 203-11[DOI][PubMed]
  • 11. Yilmaz Y. Systematic review: caspase-cleaved fragments of cytokeratin 18 - the promises and challenges of a biomarker for chronic liver disease. Aliment Pharmacol Ther. 2009; 30(11-12): 1103-9[DOI][PubMed]
  • 12. Valva P, De Matteo E, Galoppo MC, Gismondi MI, Preciado MV. Apoptosis markers related to pathogenesis of pediatric chronic hepatitis C virus infection: M30 mirrors the severity of steatosis. J Med Virol. 2010; 82(6): 949-57[DOI][PubMed]
  • 13. Kramer G, Erdal H, Mertens HJ, Nap M, Mauermann J, Steiner G, et al. Differentiation between cell death modes using measurements of different soluble forms of extracellular cytokeratin 18. Cancer Res. 2004; 64(5): 1751-6[PubMed]
  • 14. Luft T, Conzelmann M, Benner A, Rieger M, Hess M, Strohhaecker U, et al. Serum cytokeratin-18 fragments as quantitative markers of epithelial apoptosis in liver and intestinal graft-versus-host disease. Blood. 2007; 110(13): 4535-42[DOI][PubMed]
  • 15. Arthur MJ. Degradation of matrix proteins in liver fibrosis. Pathol Res Pract. 1994; 190(9-10): 825-33[DOI][PubMed]
  • 16. Athanassiadou P, Psyhoyiou H, Grapsa D, Gonidi M, Ketikoglou I, Patsouris E. Cytokeratin 8 and 18 expression in imprint smears of chronic viral hepatitis, autoimmune hepatitis and hepatocellular carcinoma. A preliminary study. Acta Cytol. 2007; 51(1): 61-5[PubMed]
  • 17. Murawaki Y, Yamada S, Ikuta Y, Kawasaki H. Clinical usefulness of serum matrix metalloproteinase-2 concentration in patients with chronic viral liver disease. J Hepatol. 1999; 30(6): 1090-8[PubMed]
  • 18. Burt AD. C. L. Oakley Lecture (1993). Cellular and molecular aspects of hepatic fibrosis. J Pathol. 1993; 170(2): 105-14[DOI][PubMed]
  • 19. Corcoran ML, Hewitt RE, Kleiner DE, Jr, Stetler-Stevenson WG. MMP-2: expression, activation and inhibition. Enzyme Protein. 1996; 49(1-3): 7-19[PubMed]
  • 20. Bantel H, Lugering A, Heidemann J, Volkmann X, Poremba C, Strassburg CP, et al. Detection of apoptotic caspase activation in sera from patients with chronic HCV infection is associated with fibrotic liver injury. Hepatology. 2004; 40(5): 1078-87[DOI][PubMed]
  • 21. Guicciardi ME, Gores GJ. Apoptosis: a mechanism of acute and chronic liver injury. Gut. 2005; 54(7): 1024-33[DOI][PubMed]
  • 22. Wieckowska A, Zein NN, Yerian LM, Lopez AR, McCullough AJ, Feldstein AE. In vivo assessment of liver cell apoptosis as a novel biomarker of disease severity in nonalcoholic fatty liver disease. Hepatology. 2006; 44(1): 27-33[DOI][PubMed]
  • 23. Boeker KH, Haberkorn CI, Michels D, Flemming P, Manns MP, Lichtinghagen R. Diagnostic potential of circulating TIMP-1 and MMP-2 as markers of liver fibrosis in patients with chronic hepatitis C. Clin Chim Acta. 2002; 316(1-2): 71-81[PubMed]
  • 24. Kuo WH, Chou FP, Lu SC, Chu SC, Hsieh YS. Significant differences in serum activities of matrix metalloproteinase-2 and -9 between HCV- and HBV-infected patients and carriers. Clin Chim Acta. 2000; 294(1-2): 157-68[PubMed]
  • 25. Papatheodoridis GV, Hadziyannis E, Tsochatzis E, Chrysanthos N, Georgiou A, Kafiri G, et al. Serum apoptotic caspase activity as a marker of severity in HBeAg-negative chronic hepatitis B virus infection. Gut. 2008; 57(4): 500-6[DOI][PubMed]
  • 26. Jazwinski AB, Thompson AJ, Clark PJ, Naggie S, Tillmann HL, Patel K. Elevated serum CK18 levels in chronic hepatitis C patients are associated with advanced fibrosis but not steatosis. J Viral Hepat. 2012; 19(4): 278-82[DOI][PubMed]
  • 27. Kronenberger B, Wagner M, Herrmann E, Mihm U, Piiper A, Sarrazin C, et al. Apoptotic cytokeratin 18 neoepitopes in serum of patients with chronic hepatitis C. J Viral Hepat. 2005; 12(3): 307-14[DOI][PubMed]
  • 28. Shi Y, Sun S, Liu Y, Li J, Zhang T, Wu H, et al. Keratin 18 phosphorylation as a progression marker of chronic hepatitis B. Virol J. 2010; 7: 70[DOI][PubMed]
  • 29. Liang B, Li Y, Zhao A, Xie F, Guo Z. Clinical utility of serum matrix metalloproteinase-2 and tissue inhibitor of metalloproteinase-2 concentrations in the assessment of liver fibrosis due to chronic hepatitis B. J Int Med Res. 2012; 40(2): 631-9[PubMed]
  • 30. Hetz H, Hoetzenecker K, Hacker S, Faybik P, Pollreisz A, Moser B, et al. Caspase-cleaved cytokeratin 18 and 20 S proteasome in liver degeneration. J Clin Lab Anal. 2007; 21(5): 277-81[DOI][PubMed]
Creative Commons License Except where otherwise noted, this work is licensed under Creative Commons Attribution Non Commercial 4.0 International License .

Search Relations:



Create Citiation Alert
via Google Reader

Readers' Comments